Timeline

how did we get here

Highlights and milestones

2022

Karolinska Development concluded a rights issue with invoX increasing its shareholding to 47.67%
February 2022
Karolinska Development Concluded a rights issue, the proceeds will finance the continued development of existing investments, new investments, and general corporate purposes.

2021

Entered an option to in-license HPK1 with Treadwell Therapeutics
November 2021
A clinical-stage oncology company which develops first-in-class and best-in-class small molecules to address unmet needs in patients with cancer.
Sino Biopharmaceutical transferred its holding in Karolinska Development
October 2021
Sino Biopharmaceutical transferred its holding in Karolinska Development (KD) to the wholly owned subsidiary invoX Pharma Ltd. KD is an early-stage, publicly-listed Nordic venture capital firm focusing on investiments in innovative life sciences companies.
Acquired a majority stake of pHion Therapeutics
June 2021
pHion is a therapeutic vaccine development company, utilising its patented peptide based drug delivery system, RALA, which when combined with nucleic acids, generates a uniquely potent therapeutic response without provoking an innate immune response.
Reached an agreement to a 100% acquisition of Softhale
March 2021
Softhale is a privately held Belgium-based respiratory company focused on the development of pharmaceutical products with superior clinical performance based upon differentiated technology delivered by our next generation Soft Mist Inhalation (SMI) device to the lungs.
invoX was established
March 2021
invoX is a wholly-owned subsidiary of Sino Biopharmaceutical LTD. It is an international expansion platform, focusing on R&D and Business Development activities outside of China.

2000

Sino Biopharm, the parent company of invoX, was listed on HKEx Growth Enterprise Market
January 2000